Drug Trial Radar · NCT06869187
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Apr 22, 2026
Study completion Sep 24, 2026
Sponsor
- Lead sponsor
- Autobahn Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment(s) can improve clinical symptoms of depression and to learn about potential effects on brain chemistry that may correlate with antidepressive effects. This is a single treatment arm, open-label, Phase 2 study of ABX-002 in up to30 adults with bipolar depression. A subset of these participants will undergo brain imaging. Five healthy volunteer participants will also be enrolled and receive no drug treatment, undergoing 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants who are experiencing an episode of depression, the study will include 4 study periods: 1. Screening Period of up to 5 weeks 2. 6-week Treatment Period 3. 2-week post dose Safety Follow-up Period. 4. 6-month postdose targeted safety follow-up period For healthy volunteers, the study will include 2 study periods: 1. Screening Period of up to 3 weeks 2. Imaging Period of up to 3 weeks.
Conditions
- Bipolar Disorder Depression
Interventions
ABX-002Drug
ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline for 17-item Hamilton Rating Scale for Depression (HAMD-17)Time frame: Weeks 6
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Autobahn Site #213
Walnut Creek, California
Autobahn Site #201
Cromwell, Connecticut
Autobahn Site #210
Hartford, Connecticut
Autobahn Site #212
Miami, Florida
Autobahn Site #215
Chicago, Illinois
Autobahn Site #216
Worcester, Massachusetts
Autobahn Site #208
Cherry Hill, New Jersey
Autobahn Site #209
Hamilton, New Jersey
Autobahn Site #205
Marlton, New Jersey
Autobahn Site #203
Brooklyn, New York
Autobahn Site #207
New York, New York
Autobahn Site #211
New York, New York
Autobahn Site #204
Staten Island, New York
Autobahn Site #214
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.